Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DEF
|
|||
| Former ID |
DAP000571
|
|||
| Drug Name |
Lisdexamfetamine
|
|||
| Synonyms |
NRP104; Lisdexamfetamine (INN); Vyvanse (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Approved | [1], [2] | |
| Company |
New River Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H25N3O
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N
|
|||
| InChI |
1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
|
|||
| InChIKey |
VOBHXZCDAVEXEY-JSGCOSHPSA-N
|
|||
| CAS Number |
CAS 608137-32-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:135925
|
|||
| ADReCS Drug ID | BADD_D01299 ; BADD_D02440 | |||
| SuperDrug ATC ID |
N06BA12
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Trace amine-associated receptor-1 (TAAR1) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (s) signalling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7213). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021977. | |||
| REF 3 | 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. | |||
| REF 4 | Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class. Bioorg Med Chem. 2011 Dec 1;19(23):7044-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.